Anadys Pharmaceuticals said last week that it had won a three-year grant from the German government to identify protein and RNA drug targets for the hepatitis C virus using technology for studying protein-protein and RNA-protein interactions.
Anadys Pharmaceuticals said last week that it had won a three-year grant from the German government to identify protein and RNA drug targets for the hepatitis C virus using technology for studying protein-protein and RNA-protein interactions.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.